MétaCan
Menu
Back to cohort
Record W2190367334 · doi:10.1530/eje-15-0873

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

2015· article· en· W2190367334 on OpenAlexaff
D B Allen, Philippe Backeljauw, Martin Bidlingmaier, Beverly M. K. Biller, Margaret Cristina da Silva Boguszewski, Pia Burman, G Butler, Kazuo Chihara, Jens Sandahl Christiansen, Stefano Cianfarani, Peter Clayton, David R. Clemmons, Pinchas Cohen, Feyza Darendelıler, Cheri Deal, David Dunger, Eva Marie Erfurth, John S. Fuqua, Adda Grimberg, Morey W. Haymond, Claire Higham, Ken K. Y. Ho, Andrew R. Hoffman, Anita Hokken-Koelega, Gudmundur Johannsson, Anders Juul, John J. Kopchick, Phillip Lee, Michaël Pollak, Sally Radovick, Leslie L. Robison, Ron G. Rosenfeld, Richard Ross, Lars Sävendahl, Paul Saenger, Henrik Toft Sørensen, Kirstine Stochholm, Christian J. Strasburger, Anthony J. Swerdlow, MO Thorner

Bibliographic record

VenueEuropean Journal of Endocrinology · 2015
Typearticle
Languageen
FieldMedicine
TopicGrowth Hormone and Insulin-like Growth Factors
Canadian institutionsCentre Hospitalier Universitaire Sainte-Justine
FundersGenentechUniversité Paris DiderotIpsenTeva Pharmaceutical IndustriesNational Institute for Health and Care ResearchNovo NordiskPediatric Endocrine SocietyPfizerEli Lilly and Company
KeywordsRecombinant DNAEndocrinologyInternal medicineCritical appraisalMedicineHuman growth hormonePosition (finance)Growth hormoneBiologyAlternative medicineHormonePathologyGenetics

Abstract

fetched live from OpenAlex

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.042
metaresearch head score (Gemma)0.121
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.042
Threshold uncertainty score0.223

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0420.121
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0020.001
Science and technology studies0.0020.002
Scholarly communication0.0050.004
Open science0.0040.002
Research integrity0.0170.018
Insufficient payload (model declined to judge)0.0060.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.301
Teacher spread0.275 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations234
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of EndocrinologySame topicGrowth Hormone and Insulin-like Growth FactorsFrench-language works237,207